$1.24
2.36% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US38341P1021
Symbol
GOSS
Sector
Industry

Gossamer Bio, Inc. Stock price

$1.24
+0.15 13.76% 1M
+0.31 33.33% 6M
+0.34 37.08% YTD
+0.72 139.98% 1Y
-11.25 90.07% 5Y
-15.46 92.57% 10Y
-15.46 92.57% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.03 2.36%
ISIN
US38341P1021
Symbol
GOSS
Sector
Industry

Key metrics

Market capitalization $288.67m
Enterprise Value $228.50m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 25.17
EV/Sales (TTM) EV/Sales 1.83
P/S ratio (TTM) P/S ratio 2.32
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $124.59m
EBIT (operating result TTM) EBIT $-54.77m
Free Cash Flow (TTM) Free Cash Flow $9.08m
Cash position $257.93m
EPS (TTM) EPS $-0.24
P/E forward negative
P/S forward 10.79
EV/Sales forward 8.54
Short interest 5.19%
Show more

Is Gossamer Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Gossamer Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Gossamer Bio, Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Gossamer Bio, Inc. forecast:

Buy
78%
Hold
22%

Financial data from Gossamer Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
125 125
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
6% 6%
28%
- Research and Development Expense 144 144
11% 11%
116%
-54 -54
67% 67%
-43%
- Depreciation and Amortization 0.58 0.58
59% 59%
0%
EBIT (Operating Income) EBIT -55 -55
67% 67%
-44%
Net Profit -51 -51
70% 70%
-41%

In millions USD.

Don't miss a Thing! We will send you all news about Gossamer Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gossamer Bio, Inc. Stock News

Neutral
Business Wire
7 days ago
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors ap...
Neutral
Seeking Alpha
29 days ago
Gossamer Bio, Inc. (NASDAQ:GOSS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard Aranda - Chief Medical Officer Caryn Peterson - EVP, Regulatory Affairs Bob Smith - Chief Commercial Officer Conference Call Participants Joseph Schwartz - SVB Leerink Andreas Argyrides - Oppenhei...
Neutral
Business Wire
29 days ago
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 3...
More Gossamer Bio, Inc. News

Company Profile

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Head office United States
CEO Faheem Hasnain
Employees 145
Founded 2015
Website www.gossamerbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today